Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026CancersOpen Access

Addition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDavid YanniNKNupur KrishnanRKRouslan Kotchetkov

Discussion

Loading...

Member takes

Overview

Real-world experience reveals no survival benefit from adding Venetoclax to Azacitidine in AML, highlighting tolerability issues.

Key Points

  • To evaluate the impact of adding Venetoclax to Azacitidine on survival and tolerability in acute myeloid leukemia patients in a real-world setting.
  • Retrospective review of patients treated with Azacitidine alone or Azacitidine plus Venetoclax
  • Assessment of administration patterns, tolerability, efficacy, and safety
  • Exclusion of patients receiving less than one cycle or those proceeding to stem cell transplant
  • Median overall survival was 18 months for Azacitidine and 14 months for Azacitidine plus Venetoclax, p = 0.905
  • 28.3% of Azacitidine patients experienced severe neutropenia compared to 56.5% for the combined treatment
  • Thrombocytopenia occurred in 15.1% of Azacitidine versus 51.2% of Azacitidine plus Venetoclax patients
  • Clinical stability or remission was achieved in 69.8% of Azacitidine patients and 69.5% in those receiving the combination treatment

Cite This Study

Yanni et al. (2026) studied this question.

synapsesocial.com/papers/69abc1765af8044f7a4ea172https://doi.org/10.3390/cancers18050841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel2016 · 5,973 citations
  2. 2Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia2003 · 2,682 citations
  3. 3How I treat patients with AML using azacitidine and venetoclax2024 · 65 citations
  4. 4Cancer Survival: An Overview of Measures, Uses, and Interpretation2014 · 301 citations
  5. 5Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia2020 · 2,928 citations